UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 174

Sortiert nach

The latest consensus on antiemetics

Current opinion in oncology, 2018-07, Vol.30 (4), p.233-239

Herrstedt, Jørn

2018

Link zum Volltext

Verfügbarkeit prüfen

Management of Cancer Cachexia: ASCO Guideline

Journal of clinical oncology, 2020-07, Vol.38 (21), p.2438-2453

2020

Link zum Volltext

Verfügbarkeit prüfen

Supportive care in cancer—a MASCC perspective

Supportive care in cancer, 2020-08, Vol.28 (8), p.3467-3475

2020

Link zum Volltext

Verfügbarkeit prüfen

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes

Drugs & aging, 2022-01, Vol.39 (1), p.1-21

2022

Link zum Volltext

Verfügbarkeit prüfen

The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients

Journal of clinical oncology, 2000-08, Vol.18 (16), p.3038-3051

2000

Link zum Volltext

Verfügbarkeit prüfen

Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature

Supportive care in cancer, 2021-07, Vol.29 (7), p.3439-3459

2021

Link zum Volltext

Verfügbarkeit prüfen

Antiemetics: an update and the MASCC guidelines applied in clinical practice

Nature clinical practice. Oncology, 2008-01, Vol.5 (1), p.32-43

Herrstedt, Jørn

2008

Link zum Volltext

Verfügbarkeit prüfen

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

European journal of cancer (1990), 2019-09, Vol.119, p.122-131

2019

Link zum Volltext

Verfügbarkeit prüfen

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Supportive care in cancer, 2017-01, Vol.25 (1), p.303-308

2017

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients

Supportive care in cancer, 2021-08, Vol.29 (8), p.4269-4275

2021

Link zum Volltext

Verfügbarkeit prüfen

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

Journal of clinical oncology, 2011-04, Vol.29 (11), p.1495-1501

2011

Link zum Volltext

Verfügbarkeit prüfen

Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer

Supportive care in cancer, 2020-04, Vol.28 (4), p.1539-1539

2020

Link zum Volltext

Verfügbarkeit prüfen

Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment

Journal of clinical oncology, 2006-09, Vol.24 (27), p.4472-4478

2006

Link zum Volltext

Verfügbarkeit prüfen

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

Supportive care in cancer, 2017-01, Vol.25 (1), p.277-288

2017

Link zum Volltext

Verfügbarkeit prüfen

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

The New England journal of medicine, 2016-12, Vol.375 (22), p.2154-2164

2016

Link zum Volltext

Verfügbarkeit prüfen

The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer - a population-based cross-sectional study

Acta oncologica, 2022-03, Vol.61 (3), p.363-370

2022

Link zum Volltext

Verfügbarkeit prüfen

5-Hydroxytryptamine3 receptor antagonists and cardiac side effects

Expert opinion on drug safety, 2014-10, Vol.13 (10), p.1407-1422

2014

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis

Supportive care in cancer, 2023-08, Vol.31 (8), p.505-505, Article 505

2023

Link zum Volltext

Verfügbarkeit prüfen

The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer

Journal of geriatric oncology, 2020-05, Vol.11 (4), p.593-602

2020

Link zum Volltext

Verfügbarkeit prüfen

Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Guideline update and results of the Perugia consensus conference

Supportive care in cancer, 2011-03, Vol.19 (Suppl 1), p.63-65

2011

Link zum Volltext

Verfügbarkeit prüfen

Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy

Supportive care in cancer, 2022-11, Vol.30 (11), p.9441-9451

2022

Link zum Volltext

Verfügbarkeit prüfen

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Supportive care in cancer, 2024-01, Vol.32 (1), p.36-36, Article 36

2024

Link zum Volltext

Verfügbarkeit prüfen

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort

European journal of cancer (1990), 2019-07, Vol.115, p.61-67

2019

Link zum Volltext

Verfügbarkeit prüfen

2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents

Supportive care in cancer, 2024-01, Vol.32 (1), p.45-45, Article 45

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy

Thrombosis research, 2023-01, Vol.221, p.164-172

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 174

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(159)

Publikationsform

Sprache

Englisch
(168)
Japanisch
(39)
Dänisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(127)
Life Sciences & Biomedicine
(126)
Humans
(124)
Oncology
(112)
Chemotherapy
(50)
Antiemetics - Therapeutic Use
(44)
Female
(44)
Vomiting - Chemically Induced
(44)
Antineoplastic Agents - Adverse Effects
(41)
Vomiting - Prevention & Control
(40)
Nausea - Chemically Induced
(37)
Nausea
(36)
Nausea - Prevention & Control
(36)
Health Care Sciences & Services
(35)
Medicine
(33)
Rehabilitation
(33)
Aged
(30)
Middle Aged
(30)
Cancer
(29)
Medicine & Public Health
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The latest consensus on antiemetics

Management of Cancer Cachexia: ASCO Guideline

Supportive care in cancer—a MASCC perspective

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes

The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients

Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature

Antiemetics: an update and the MASCC guidelines applied in clinical practice

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer

Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer - a population-based cross-sectional study

5-Hydroxytryptamine3 receptor antagonists and cardiac side effects

Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis

The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer

Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Guideline update and results of the Perugia consensus conference

Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort

2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents

Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy

Suchergebnisse filtern